C-reactive protein in patients with COPD, control smokers and non-smokers
Victor Pinto-Plata,Hana Müllerová,John Toso,Maurille Feudjo-Tepie,Joan B. Soriano,R. Vessey,Bartolome R. Celli +6 more
Reads0
Chats0
TLDR
CRP levels are raised in COPD patients without clinically relevant IHD and independent of cigarette smoking, and reduced in patients with COPD using ICS, suggesting CRP may be a systemic marker of the inflammatory process that occurs in patientswith COPD.Abstract:
Background: Patients with chronic obstructive pulmonary disease (COPD) have raised serum levels of C reactive protein (CRP). This may be related directly to COPD and its associated systemic inflammation or secondary to other factors such as concomitant ischaemic heart disease (IHD) or smoking status. The aim of this study was to evaluate IHD and smoking as potential causes of raised CRP levels in COPD and to test the association between inhaled corticosteroid (ICS) use and serum CRP levels. Methods: Cross sectional analyses comparing cohorts of 88 patients with COPD, 33 smokers (S), and 38 non-smoker (NS) controls were performed. Clinical assessments included a complete medical history, pulmonary function, 6 minute walk test (6MWT), cardiopulmonary exercise test, and high sensitivity serum CRP measurements. Results: Serum CRP levels were significantly higher in patients with COPD (5.03 (1.51) mg/l) than in controls (adjusted odds ratio 9.51; 95% confidence interval 2.97 to 30.45) but were similar in the two control groups (S: 2.02 (1.04) mg/l; NS: 2.24 (1.04) mg/l). There was no clinical or exercise evidence of unstable IHD in any of the subjects. CRP levels were lower in COPD patients treated with ICS than in those not treated (3.7 (3.0) mg/l v 6.3 (3.6) mg/l); this association was confirmed in an adjusted regression model (p Conclusion: CRP levels are raised in COPD patients without clinically relevant IHD and independent of cigarette smoking, and reduced in patients with COPD using ICS. CRP may be a systemic marker of the inflammatory process that occurs in patients with COPD.read more
Citations
More filters
Journal ArticleDOI
The potential risks of nanomaterials: a review carried out for ECETOC
Paul J. A. Borm,David Robbins,Stephan Haubold,Thomas A. J. Kuhlbusch,Heinz Fissan,Ken Donaldson,Roel P. F. Schins,Vicki Stone,Wolfgang G. Kreyling,Jürgen Lademann,Jean Krutmann,David B. Warheit,Eva Oberdörster +12 more
TL;DR: This review shows that only few specific nanoparticles have been investigated in a limited number of test systems and extrapolation of this data to other materials is not possible, and limited ecotoxicological data for nanomaterials precludes a systematic assessment of the impact of Nanoparticles on ecosystems.
Journal ArticleDOI
Outcomes for COPD pharmacological trials: From lung function to biomarkers
Mario Cazzola,William MacNee,Fernando J. Martinez,Klaus F. Rabe,L. G. Franciosi,Peter J. Barnes,Vito Brusasco,PS Burge,Peter M.A. Calverley,Bartolome R. Celli,Paul W. Jones,Donald A. Mahler,Barry Make,Marc Miravitlles,Clive P. Page,Paolo Palange,David G. Parr,Massimo Pistolesi,S. I. Rennard,MP Rutten-van Mölken,Robert A. Stockley,Sean D. Sullivan,Jadwiga A. Wedzicha,Emiel F.M. Wouters +23 more
TL;DR: The American Thoracic Society/European Respiratory Society jointly created a Task Force on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers.
Journal ArticleDOI
C-reactive Protein As a Predictor of Prognosis in Chronic Obstructive Pulmonary Disease
Morten Dahl,Jørgen Vestbo,Peter Lange,Stig E. Bojesen,Anne Tybjærg-Hansen,Børge G. Nordestgaard +5 more
TL;DR: CRP is a strong and independent predictor of future COPD outcomes in individuals with airway obstruction and among those older than 70 yr with a tobacco consumption above 15 g/d and an FEV(1)% predicted of less than 50.
Journal ArticleDOI
Comorbidities in Chronic Obstructive Pulmonary Disease
TL;DR: Comorbidities such as cardiac disease, diabetes mellitus, hypertension, osteoporosis, and psychological disorders are commonly reported in patients with chronic obstructive pulmonary disease (COPD) and are relevant not only to the understanding of the real burden of COPD but also to the development of effective management strategies.
Journal ArticleDOI
Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease.
Bartolome R. Celli,Nicholas Locantore,Julie C. Yates,Ruth Tal-Singer,Bruce E. Miller,Per Bakke,Peter M.A. Calverley,Harvey O. Coxson,Courtney Crim,Lisa D. Edwards,David A. Lomas,Annelyse Duvoix,William MacNee,Stephen I. Rennard,Edwin K. Silverman,Jørgen Vestbo,Jørgen Vestbo,Emiel F.M. Wouters,Alvar Agusti +18 more
TL;DR: The addition of a panel of selected biomarkers improves the ability of established clinical variables to predict mortality in chronic obstructive pulmonary disease.
References
More filters
Journal ArticleDOI
Measuring agreement in method comparison studies
J M Bland,Douglas G. Altman +1 more
TL;DR: The 95% limits of agreement, estimated by mean difference 1.96 standard deviation of the differences, provide an interval within which 95% of differences between measurements by the two methods are expected to lie.
Journal ArticleDOI
Standardization of Spirometry, 1994 Update. American Thoracic Society.
R. Crapo,John L. Hankinson,Charles G. Irvin,Neil R. MacIntyre,K. Z. Voter,Robert A. Wise,Brian L. Graham,C. O'Donnell,P. Paoletti,J. Roca,G. Veigi +10 more
Journal ArticleDOI
Markers of Inflammation and Cardiovascular Disease Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association
Thomas A. Pearson,George A. Mensah,R. Wayne Alexander,Jeffrey L. Anderson,Richard O. Cannon,Michael H. Criqui,Yazid Y. Fadl,Stephen P. Fortmann,Yuling Hong,Gary L. Myers,Nader Rifai,Sidney C. Smith,Kathryn A. Taubert,Russell P. Tracy,Frank Vinicor +14 more
TL;DR: There has been no consensus from professional societies or governmental agencies as to how these assays of markers of inflammation should be used in clinical practice, and a workshop to address these issues was convened in Atlanta, Ga.
Journal ArticleDOI
The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease
Bartolome R. Celli,Claudia Cote,Jose M. Marin,Ciro Casanova,Maria Montes de Oca,Reina A. Mendez,Victor Pinto Plata,Howard Cabral +7 more
TL;DR: The BODE index, a simple multidimensional grading system, is better than the FEV1 at predicting the risk of death from any cause and from respiratory causes among patients with COPD.
Book
Chronic obstructive pulmonary disease
TL;DR: The most important bacterial causes of exacerbations of COPD are nontypeable Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae and Chlamydia pneumoniae.
Related Papers (5)
Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis
Why Are Patients With Chronic Obstructive Pulmonary Disease at Increased Risk of Cardiovascular Diseases? The Potential Role of Systemic Inflammation in Chronic Obstructive Pulmonary Disease
Don D. Sin,S. F. Paul Man +1 more